Head-to-head Study of 68Ga-MGS5 Versus 68Ga-DOTATATE PET/CT in Patients With Medullary Thyroid Carcinoma: a Prospective Study
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
Cholecystokinin-2 (CCK2) receptor is overexpressed in more than 90% of MTC cases, and preclinical studies have shown that 68Ga-MGS5 (targeting CCK2) has good stability in vivo and is promising for diagnosis and staging of MTC. This prospective study will compare the diagnostic effects of 68Ga-MGS5 and 68Ga-DOTATATE on MTC primary foci, lymph node metastasis, and distant metastasis, and explore the effect of 68Ga-MGS5 PET/CT on the clinical staging (TNM staging) of MTC.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:
• Patients of either gender, aged ≥ 18 years and ≤80 years.
• Patients with pathologic findings confirming the diagnosis of MTC
• Patients with MTC recurrence
• Signed written consent
Locations
Other Locations
China
Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University
RECRUITING
Fuzhou
Contact Information
Primary
Weibing Miao
miaoweibing@126.com
86-0591-87981618
Backup
jieling zheng
775304265@qq.com
86-599-87981619
Time Frame
Start Date: 2023-06-21
Estimated Completion Date: 2025-07
Participants
Target number of participants: 20
Treatments
Experimental: Patients will undergo a 68Ga-MGS5 PET/CTF and 68Ga-DOTATATE PET/CT
MTC Patients received 68Ga-DOTATATE PET/CT imaging and a single injection of 68Ga-MGS5 and two PET/CT scans 1 hour and 2 hours after the injection within one week.
Related Therapeutic Areas
Sponsors
Leads: First Affiliated Hospital of Fujian Medical University